drugset / Trial / NCT06732232
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologouschimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed/refractory multiple myeloma.
Timeline
- Start
- 2024-12-12
- Primary completion
- 2027-12-12
- Completion
- 2027-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19/CD20/BCMA CAR-T | Cell therapy | — | Intravenous |